A new multi-state study led by the Centers for Disease Control and Prevention’s (CDC) VISION Network—including Regenstrief Institute—has provided the most comprehensive assessment to date of the effectiveness of 2023–2024 COVID-19 vaccines among adults in the U.S. during the XBB and JN.1 omicron subvariant waves.
Updated COVID vaccine reduces risk of severe illness and death, especially for high-risk adults
